796875-26-8Relevant articles and documents
Diarylimidazolyl oxadiazole and thiadiazole derivatives as cannabinoid CB1 receptor antagonists
Kim, Jong Yup,Seo, Hee Jeong,Lee, Sung-Han,Jung, Myung Eun,Ahn, Kwangwoo,Kim, Jeongmin,Lee, Jinhwa
body text, p. 142 - 145 (2009/05/30)
Since the CB1 receptor antagonist SR141716 (rimonabant) was reported to modulate food intake, CB1 antagonism has been considered as a new therapeutic target in the treatment of obesity. Several series of derivatives based on diarylimidazolyl oxadiazole an